A Phase II, Placebo-Controlled, Double-Blind, Dose-Ranging (35mg/Day or 70 mg/Day), Randomized, Study of Cutaneous Dihydrotestosterone (DHT)-Gel (0.7% Hydroalcoholic Gel) in Older Hypogonadal Males Ages 55-80 Years: Effect on Body Composition, Libido, and Physical and Sexual Functioning
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2012
At a glance
- Drugs Androstanolone (Primary)
- Indications Hypogonadism
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 11 Jul 2012 Planned end date (1 Dec 2012 ) added as reported by ClinicalTrials.gov.
- 30 Oct 2006 New trial record.